Acumen expects to report topline ALTITUDE-AD Phase 2 data in November; Q3 cash of $78.6M expected to last into early 2027

Acumen Pharmaceuticals expects to report topline results for ALTITUDE-AD, a Phase 2 study of sabirnetug (ACU193) for early Alzheimer's disease, in November 2026. The company ended Q3 with about $78.6M in cash, expected to last into early 2027.

Detected & updated continuously · Source: Nebula